John E. Davis Sells 6,457 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 6,457 shares of Artivion stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $176,340.67. Following the transaction, the insider now owns 160,631 shares of the company’s stock, valued at approximately $4,386,832.61. The trade was a 3.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Artivion Stock Down 0.9 %

Shares of NYSE AORT traded down $0.22 during mid-day trading on Wednesday, reaching $25.34. 295,834 shares of the company’s stock were exchanged, compared to its average volume of 385,115. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -1,268.25 and a beta of 1.75. Artivion, Inc. has a twelve month low of $18.38 and a twelve month high of $32.33. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $29.68 and a 200 day simple moving average of $27.83.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The firm had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. As a group, equities analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on AORT shares. JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC decreased their price target on Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday. Oppenheimer increased their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Finally, Stifel Nicolaus cut their price target on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $31.40.

Hedge Funds Weigh In On Artivion

Institutional investors have recently modified their holdings of the business. Squarepoint Ops LLC grew its holdings in shares of Artivion by 30.8% during the fourth quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock worth $1,021,000 after purchasing an additional 8,404 shares during the last quarter. Tidal Investments LLC grew its holdings in Artivion by 14.5% during the 4th quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock worth $5,141,000 after acquiring an additional 22,804 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Artivion during the fourth quarter valued at $64,000. Point72 Asset Management L.P. bought a new stake in shares of Artivion in the fourth quarter worth $5,573,000. Finally, ProShare Advisors LLC lifted its holdings in Artivion by 44.7% during the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock worth $341,000 after buying an additional 3,683 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.